Valproate-associated reproductive and metabolic abnormalities: Are epileptic women at greater risk than bipolar women?

Simple item page
dc.contributor.authorAkdeniz F.
dc.contributor.authorTaneli F.
dc.contributor.authorNoyan A.
dc.contributor.authorYüncü Z.
dc.contributor.authorVahip S.
dc.date.accessioned2024-07-22T08:25:01Z
dc.date.available2024-07-22T08:25:01Z
dc.date.issued2003
dc.description.abstractObjective: Evidence indicates that valproate (VPA) may have an adverse impact on reproductive endocrine and metabolic functions in women with epilepsy. This study explores whether the association of VPA with reproductive endocrine abnormalities is applicable to women with bipolar disorder (BD) or is unique to women with epilepsy. Methods: Thirty female patients aged 18-40 years with a DSM-IV diagnosis of BD (15 on lithium monotherapy and 15 on VPA monotherapy or VPA in combination with lithium therapy) and 15 with idiopathic generalized epilepsy (IGE) on VPA monotherapy were evaluated for reproductive endocrine functioning and metabolic parameters. Results: The menarche age, mean length of menstrual cycle and mean length of menses were not significantly different between groups. None of the bipolar patients on lithium, three (20%) of the bipolar patients on VPA and seven (47%) of the epileptic patients on VPA reported menstrual disturbances. Hirsutism scores of the epilepsy group were significantly higher than those bipolar women, regardless of treatment. Serum total testosterone levels were significantly higher in patients (both with BD and with IGE) treated with VPA than in those treated with lithium. Serum FSH levels were significantly lower and LH-to-FSH ratio was significantly higher in patients with epilepsy than in patients with BD, regardless of treatment. The weight parameters and lipid values investigated did not differ significantly between the groups. Conclusion: The study supports the conclusion that VPA may be associated with menstrual abnormalities and increased total testosterone levels in both bipolar and epileptic patients although women with BD did not show clinical features of hyperandrogenism (menstrual abnormalities, hirsutism and truncal obesity) as did frequently as women with epilepsy. © 2002 Elsevier Science Inc. All rights reserved.
dc.identifier.DOI-ID10.1016/S0278-5846(02)00341-X
dc.identifier.issn02785846
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/20237
dc.language.isoEnglish
dc.publisherElsevier Inc.
dc.subjectlithium
dc.subjectvalproic acid
dc.subjectadult
dc.subjectarticle
dc.subjectbipolar disorder
dc.subjectclinical article
dc.subjectclinical feature
dc.subjectcontrolled study
dc.subjectepilepsy
dc.subjectfemale
dc.subjectfollitropin blood level
dc.subjecthirsutism
dc.subjecthuman
dc.subjecthyperandrogenism
dc.subjectluteinizing hormone blood level
dc.subjectmenarche
dc.subjectmenstrual cycle
dc.subjectmetabolic regulation
dc.subjectobesity
dc.subjectpremenstrual syndrome
dc.subjectreproduction
dc.subjectrisk assessment
dc.subjectside effect
dc.subjecttestosterone blood level
dc.titleValproate-associated reproductive and metabolic abnormalities: Are epileptic women at greater risk than bipolar women?
dc.typeArticle

Files

Collections

Scopus Koleksiyonu